Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. (Q39942521)

15 September 2017

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. (English)

1 reference

15 September 2017

Joseph M Gozgit

1

1 reference

15 September 2017

Geraldine Bebernitz

2

1 reference

15 September 2017

Pankaj Patil

3

1 reference

15 September 2017

Minwei Ye

4

1 reference

15 September 2017

Julie Parmentier

5

1 reference

15 September 2017

Jiaquan Wu

6

1 reference

15 September 2017

Nancy Su

7

1 reference

15 September 2017

Tao Wang

8

1 reference

15 September 2017

Stephanos Ioannidis

9

1 reference

15 September 2017

Audrey Davies

10

1 reference

15 September 2017

Dennis Huszar

11

1 reference

15 September 2017

Michael Zinda

12

1 reference

15 September 2017

language of work or name

English

0 references

publication date

4 September 2008

1 reference

Journal of Biological Chemistry

15 September 2017

1 reference

15 September 2017

283

1 reference

15 September 2017

47

1 reference

15 September 2017

32334-32343

1 reference

Janus kinases: components of multiple signaling pathways

15 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Oncogenic mechanisms in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Hematopoietic cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The JAK-STAT pathway: a therapeutic target in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Unknotting the roles of Bcl-2 and Bcl-xL in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The survival kinases Akt and Pim as potential pharmacological targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The serine/threonine kinase Pim-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Pharmacological manipulation of cell death: clinical applications in sight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Activated Jak2 with the V617F point mutation promotes G1/S phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

JAK2 V617F: implications for thrombosis in myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M803813200

21 January 2018

Identifiers

DOI

10.1074/JBC.M803813200

1 reference

15 September 2017

1 reference